دورية أكاديمية
أعرض في EDS

Anaemia of cancer: an overview of mechanisms involved in its pathogenesis.

التفاصيل البيبلوغرافية
العنوان: Anaemia of cancer: an overview of mechanisms involved in its pathogenesis.
المؤلفون: Grotto HZ; Department of Clinical Pathology, Faculty of Medical Sciences, State University of Campinas - UNICAMP, CP 6111, 13083-970, Campinas, SP, Brazil. grotto@fcm.unicamp.br
المصدر: Medical oncology (Northwood, London, England) [Med Oncol] 2008; Vol. 25 (1), pp. 12-21. Date of Electronic Publication: 2007 Sep 02.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: Springer Country of Publication: United States NLM ID: 9435512 Publication Model: Print-Electronic Cited Medium: Print ISSN: 1357-0560 (Print) Linking ISSN: 13570560 NLM ISO Abbreviation: Med Oncol Subsets: MEDLINE
أسماء مطبوعة: Publication: 2011- : New York : Springer
Original Publication: Northwood, Middlesex, England : Science and Technology Letters, c1994-
مواضيع طبية MeSH: Anemia/*etiology , Neoplasms/*complications, Anemia/epidemiology ; Animals ; Antimicrobial Cationic Peptides/physiology ; Cytokines/physiology ; Hepcidins ; Humans ; Nitric Oxide/physiology ; Prevalence
مستخلص: Anaemia is a common complication in cancer patients. The decrease in haemoglobin is associated with an impaired quality of life, poorer response to therapy and worse prognosis. Numerous factors are involved in the physiopathology of cancer-related anaemia. Some factors such as bleeding, bone marrow infiltration, the effects of chemoradiotherapy and associated nutritional deficiencies are related to the disease itself. In addition, the interaction of the immune system with iron metabolism and erythropoiesis has been shown to be an important factor in the development of anaemia in cancer patients and can be seen in the action of several cytokines on different iron-homeostasis and erythrocyte-cell-production pathways. Some inhibitory cytokines, such as tumour necrosis factor-alpha and interleukin-1, act on the suppression of erythroid precursor cells and erythropoietic production and response; others, such as interleukins 1 and 6 and hepcidin, impair iron metabolism, causing iron to be diverted from erythropoiesis and retained within the reticuloendothelial system. The main mechanisms involved in the development of cancer-related anaemia are discussed in this review.
Number of References: 111
References: Cancer Res. 1991 Dec 1;51(23 Pt 1):6250-3. (PMID: 1933885)
Lancet Oncol. 2003 Aug;4(8):459-60. (PMID: 12901958)
Am J Clin Oncol. 2002 Aug;25(4):371-9. (PMID: 12151968)
Trans R Soc Trop Med Hyg. 1994 Jan-Feb;88(1):75. (PMID: 8154010)
Int J Biochem Cell Biol. 2002 Apr;34(4):309-14. (PMID: 11854028)
Semin Oncol. 2001 Apr;28(2 Suppl 8):49-53. (PMID: 11395853)
Eur J Cancer. 2007 Jan;43(2):258-70. (PMID: 17182241)
Clin Investig. 1993 Jan;71(1):37-41. (PMID: 8453258)
Best Pract Res Clin Haematol. 2005 Jun;18(2):171-82. (PMID: 15737883)
Nature. 2002 May 30;417(6888):552-5. (PMID: 12037568)
Curr Drug Metab. 2002 Apr;3(2):175-87. (PMID: 12003349)
Cancer. 2001 Jun 15;91(12):2214-21. (PMID: 11413508)
Arch Pathol Lab Med. 1994 Apr;118(4):371-9. (PMID: 8166587)
Semin Hematol. 1998 Jan;35(1):35-54. (PMID: 9460808)
Blood. 1994 Jan 1;83(1):260-8. (PMID: 7506082)
Semin Hematol. 2000 Oct;37(4 Suppl 6):14-7. (PMID: 11068951)
Blood. 1996 Aug 1;88(3):1070-8. (PMID: 8704216)
Eur J Haematol. 2006 Nov;77(5):378-86. (PMID: 17044835)
Eur J Cancer. 2001 Sep;37(13):1617-23. (PMID: 11527686)
Eur J Cancer Care (Engl). 1995 Mar;4(1):20-32. (PMID: 7620651)
Semin Oncol. 2000 Apr;27(2 Suppl 4):4-8; discussion 16-7. (PMID: 10847301)
Ann Oncol. 1992 Dec;3(10):819-24. (PMID: 1286044)
Blood. 2003 Apr 1;101(7):2461-3. (PMID: 12433676)
J Clin Oncol. 2001 Jun 1;19(11):2865-74. (PMID: 11387359)
Physiology (Bethesda). 2006 Apr;21:115-23. (PMID: 16565477)
Cancer Res. 1993 Jan 15;53(2):260-5. (PMID: 8417818)
Clin Chim Acta. 1998 Aug 10;276(1):63-74. (PMID: 9760020)
Br J Haematol. 2003 Aug;122(3):394-403. (PMID: 12877666)
Best Pract Res Clin Haematol. 2005 Jun;18(2):183-201. (PMID: 15737884)
Oncologist. 2003;8 Suppl 3:18-29. (PMID: 14671225)
J Clin Pharm Ther. 2001 Oct;26(5):319-29. (PMID: 11679022)
Cancer Res. 1986 Feb;46(2):950-5. (PMID: 3940654)
Blood. 2003 May 15;101(10):4148-54. (PMID: 12522003)
Nature. 1996 Jan 4;379(6560):88-91. (PMID: 8538748)
Cancer. 2006 Apr 1;106(7):1554-9. (PMID: 16518817)
Semin Oncol. 2001 Apr;28(2 Suppl 8):29-35. (PMID: 11395850)
Oncologist. 2007 Apr;12(4):362-5. (PMID: 17470677)
Br J Cancer. 2000 Jan;82(1):93-7. (PMID: 10638973)
J Biol Chem. 2001 Mar 16;276(11):7811-9. (PMID: 11113132)
Semin Oncol. 2002 Jun;29(3 Suppl 8):88-91. (PMID: 12082660)
Cancer. 2001 Aug 15;92(4):903-8. (PMID: 11550164)
Carcinogenesis. 2003 Jun;24(6):1021-9. (PMID: 12807756)
Int J Radiat Oncol Biol Phys. 1998 Nov 1;42(4):843-8. (PMID: 9845108)
Clin Chem. 1991 Dec;37(12):2038-42. (PMID: 1764778)
J Clin Invest. 2004 May;113(9):1271-6. (PMID: 15124018)
Blood. 1995 Aug 1;86(3):900-5. (PMID: 7542502)
J Intern Med. 2004 Aug;256(2):145-52. (PMID: 15257727)
Blood. 2005 Sep 1;106(5):1864-6. (PMID: 15886319)
Nat Rev Cancer. 2002 Jan;2(1):38-47. (PMID: 11902584)
Immunol Lett. 1991 Sep;30(1):101-6. (PMID: 1959936)
Ann Oncol. 1997;8 Suppl 1:93-101. (PMID: 9187440)
Cancer Treat Rep. 1985 Jul-Aug;69(7-8):777-82. (PMID: 3160460)
Wien Klin Wochenschr. 2006 Aug;118(15-16):442-62. (PMID: 16957974)
Semin Oncol. 1998 Jun;25(3 Suppl 7):43-6. (PMID: 9671330)
Biochem J. 1995 Sep 1;310 ( Pt 2):533-8. (PMID: 7544575)
J Clin Invest. 1993 Mar;91(3):969-76. (PMID: 8450071)
Exp Hematol. 1990 Feb;18(2):109-13. (PMID: 2303102)
Ann Oncol. 2000 Aug;11(8):971-5. (PMID: 11038033)
Blood Rev. 2002 Jun;16(2):87-96. (PMID: 12127952)
Exp Hematol. 1990 May;18(4):311-5. (PMID: 2323367)
FEBS Lett. 2000 Sep 1;480(2-3):147-50. (PMID: 11034317)
Lancet. 2003 Oct 18;362(9392):1255-60. (PMID: 14575968)
J Natl Cancer Inst. 2001 Aug 15;93(16):1204-14. (PMID: 11504766)
J Clin Invest. 1995 Aug;96(2):1085-92. (PMID: 7543491)
Semin Hematol. 1966 Oct;3(4):351-75. (PMID: 5341723)
Oncology (Williston Park). 2002 Sep;16(9 Suppl 10):25-33. (PMID: 12380952)
Eur J Cancer. 2004 Oct;40(15):2293-306. (PMID: 15454256)
Proc Natl Acad Sci U S A. 2001 Jul 17;98 (15):8780-5. (PMID: 11447267)
FEBS Lett. 1993 Apr 19;321(1):89-92. (PMID: 8385632)
Curr Opin Immunol. 1992 Feb;4(1):3-7. (PMID: 1596366)
Blood. 1992 Apr 15;79(8):1987-94. (PMID: 1373333)
Cancer Treat Rev. 2000 Aug;26(4):303-11. (PMID: 10913385)
Exp Dermatol. 1999 Jun;8(3):167-76. (PMID: 10389633)
J Natl Cancer Inst. 2006 May 17;98(10):708-14. (PMID: 16705125)
Eur J Haematol. 1993 Feb;50(2):90-4. (PMID: 8440363)
Oncology. 2005;69 Suppl 2:2-7. (PMID: 16244504)
Oncology (Williston Park). 2006 Jul;20(8 Suppl 6):25-8. (PMID: 16925108)
Semin Oncol. 2001 Apr;28(2 Suppl 8):7-14. (PMID: 11395846)
J Biol Chem. 1990 Aug 25;265(24):14572-8. (PMID: 1696948)
Clin Exp Rheumatol. 1991 May-Jun;9(3):241-6. (PMID: 1879083)
Eur J Cancer. 1998 Oct;34(11):1670-6. (PMID: 9893650)
Kidney Int Suppl. 1999 Mar;69:S12-7. (PMID: 10084281)
J Biol Chem. 2001 Mar 16;276(11):7806-10. (PMID: 11113131)
Cell. 1998 May 1;93(3):385-95. (PMID: 9590173)
FASEB J. 1989 Mar;3(5):1637-43. (PMID: 2784116)
Eur J Biochem. 2000 Nov;267(22):6586-93. (PMID: 11054110)
J Natl Cancer Inst. 1999 Oct 6;91(19):1616-34. (PMID: 10511589)
J Cell Physiol. 1992 Jan;150(1):59-64. (PMID: 1730787)
Eur J Haematol. 1992 May;48(5):244-8. (PMID: 1644156)
Cancer. 1999 Oct 15;86(8):1528-36. (PMID: 10526282)
Life Sci. 1992;50(4):301-8. (PMID: 1310133)
Cancer J Sci Am. 1998 Jul-Aug;4(4):218-23. (PMID: 9689978)
Eur J Med Res. 1999 Apr 27;4(4):156-60. (PMID: 10205291)
Cancer Prev Control. 1999 Jun;3(3):207-12. (PMID: 10474769)
J Clin Oncol. 2002 Jan 15;20(2):601-3. (PMID: 11786593)
J Clin Invest. 1986 Dec;78(6):1694-700. (PMID: 3023450)
Cancer Res. 1990 Jun 1;50(11):3339-44. (PMID: 2334928)
Proc Natl Acad Sci U S A. 1991 Jun 1;88(11):4946-50. (PMID: 2052577)
Blood. 1997 Jan 1;89(1):1-25. (PMID: 8978272)
Crit Rev Oncol Hematol. 1995 Nov;21(1-3):1-18. (PMID: 8822494)
Eur J Haematol. 1999 May;62(5):341-5. (PMID: 10359064)
Science. 2004 Dec 17;306(5704):2090-3. (PMID: 15514116)
Blood. 2002 May 15;99(10):3505-16. (PMID: 11986201)
Eur J Haematol. 1991 Feb;46(2):65-70. (PMID: 1899833)
المشرفين على المادة: 0 (Antimicrobial Cationic Peptides)
0 (Cytokines)
0 (HAMP protein, human)
0 (Hepcidins)
31C4KY9ESH (Nitric Oxide)
تواريخ الأحداث: Date Created: 20080112 Date Completed: 20080506 Latest Revision: 20181113
رمز التحديث: 20231215
DOI: 10.1007/s12032-007-9000-8
PMID: 18188710
قاعدة البيانات: MEDLINE
الوصف
تدمد:1357-0560
DOI:10.1007/s12032-007-9000-8